Aquestive Therapeutics, Inc.
AQST
$4.06
$0.041.00%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 9.67% | -5.43% | -50.23% | -27.65% | -10.14% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.67% | -5.43% | -50.23% | -27.65% | -10.14% |
| Cost of Revenue | 29.12% | 1.56% | 0.77% | -16.79% | -3.40% |
| Gross Profit | -2.29% | -8.83% | -65.05% | -33.87% | -13.84% |
| SG&A Expenses | 105.02% | 25.76% | 11.88% | 78.43% | 67.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 64.48% | 11.24% | 6.62% | 33.67% | 48.66% |
| Operating Income | -112.38% | -38.47% | -20,769.09% | -116.20% | -247.20% |
| Income Before Tax | -86.65% | -34.21% | -393.55% | -78.75% | -113.10% |
| Income Tax Expenses | -- | -- | -- | -- | -113.86% |
| Earnings from Continuing Operations | -86.81% | -34.21% | -393.55% | -78.75% | -110.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -86.81% | -34.21% | -393.55% | -78.75% | -110.27% |
| EBIT | -112.38% | -38.47% | -20,769.09% | -116.20% | -247.20% |
| EBITDA | -113.91% | -39.47% | -4,418.46% | -119.73% | -292.42% |
| EPS Basic | -39.68% | -10.52% | -351.66% | -37.75% | -54.93% |
| Normalized Basic EPS | -50.09% | -10.51% | -191.78% | -37.83% | -67.64% |
| EPS Diluted | -39.68% | -10.52% | -351.66% | -37.75% | -54.93% |
| Normalized Diluted EPS | -50.09% | -10.51% | -191.78% | -37.83% | -67.64% |
| Average Basic Shares Outstanding | 33.74% | 21.41% | 9.26% | 29.73% | 35.71% |
| Average Diluted Shares Outstanding | 33.74% | 21.41% | 9.26% | 29.73% | 35.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |